Trial Profile
An observational study evaluated patient characteristics and overall survival in post-docetaxel metastatic castration-resistant prostate cancer patients.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2016
Price :
$35
*
At a glance
- Drugs Abiraterone (Primary) ; Cabazitaxel (Primary) ; Docetaxel (Primary) ; Enzalutamide (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 02 Jun 2016 New trial record
- 25 May 2016 Results presented at the 21st Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research